<DOC>
	<DOCNO>NCT00221195</DOCNO>
	<brief_summary>The objective study ass whether prophylactic therapy activate prothrombin complex concentrate ( FEIBA ) result significant reduction number bleed patient hemophilia persistent high respond inhibitor .</brief_summary>
	<brief_title>Efficacy Study Activated Prothrombin Complex Prevention Bleeds Hemophilia A With Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<criteria>hemophilia A , severity , document history hightiter inhibitor ( &gt; 5BU ) ; current use bypassing agent ( PCCs , aPCCs rFVIIa ) treatment bleeds ; &gt; /= 6 bleeds require bypass therapy previous 6 month concomitant immune tolerance therapy ; clinically symptomatic liver disease , platelet count less 100,000</criteria>
	<gender>All</gender>
	<minimum_age>24 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>